Skip to main content

Risk-Adapted Donor Selection in Patients with Acute Myeloid Leukemia

In brief

High-risk AML patients had 14-point higher 3-year survival with matched unrelated donors

In a Taiwan registry study of 1,963 adults with AML undergoing a first transplant, 3-year survival in high or very high-risk disease was 42.7% with matched unrelated donors versus 28.5% with other donor types. The advantage was linked to lower non-relapse mortality, not fewer relapses; because this was an observational study, whether the pattern applies beyond this setting remains uncertain.

Journal
Transplantation and cellular therapy (Q1)
Published
6 November 2026
Study design
Unclassified
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Xavier Cheng-Hong Tsai, Jia-Hau Liu, Liang-Tsai Hsiao, Tzu-Ting Chen, Yi-Jiun Su, Sin-Syue Li, et al.
PMID
42994757
DOI
10.1016/j.jtct.2026.11.009

Why clinicians should know about it

  • Picked for Hematology (paper of the day, 10 November 2026): Large AML transplant registry compares donor choices by disease risk

Abstract

BACKGROUND: The optimal donor for adults with acute myeloid leukemia (AML) who lack a matched sibling donor (MSD) remains uncertain in Asian practice, where antithymocyte globulin (ATG)-based graft-versus-host disease (GvHD) prophylaxis is common. OBJECTIVES: To compare outcomes after MSD, matched unrelated donor (MUD), mismatched unrelated donor (MMUD), and haploidentical donor (HID) transplantation, and to test whether disease risk modifies the donor effect. STUDY DESIGN: We analyzed 1,963 adults with AML who underwent first allogeneic hematopoietic stem cell transplantation (HSCT) in the Taiwan Blood and Marrow Transplantation Registry between 2009 and 2025. We applied a doubly robust strategy combining multinomial propensity-score inverse probability of treatment weighting (IPTW) with multivariable Cox and Fine-Gray regression. GvHD was evaluated as a mediator by landmark and causal mediation analyses. RESULTS: Using MUD as reference, all three other donor types had inferior overall survival (OS), reaching significance for HID (hazard ratio [HR] 1.34, p=0.022) and MMUD (HR 1.31, p=0.026) but not for MSD (HR 1.18, p=0.131). Non-relapse mortality (NRM) was higher after HID (HR 1.61, p=0.011), with a trend after MMUD (HR 1.38, p=0.079), and GvHD-free, relapse-free survival (GRFS) was inferior after MSD (HR 1.40, p<0.001) and HID (HR 1.31, p=0.008). Relapse did not differ by donor type, indicating that the survival advantage of MUD operates through lower NRM. Causal mediation analysis did not attribute the MUD-HID survival difference to GvHD. Disease risk modified the donor effect on OS (interaction p=0.028). In high/very-high-risk disease, MUD was superior to MSD, MMUD, and HID (HR 1.44, 1.78, and 1.74, respectively), with 3-year OS of 42.7% after MUD and 28.5% after other donors. In low/intermediate-risk disease, OS did not differ by donor type. CONCLUSIONS: MUD was associated with better OS than alternative donors (MMUD and HID) through lower NRM, and its survival benefit was largest in high-risk disease. Donor selection in AML can be risk-adapted: MUD could be prioritized in high-risk disease, whereas GRFS should guide donor choice in lower-risk disease, where OS is similar across donor types.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.